Women With Breast Cancer
The Impact of Sleep on Cancer Related Cognitive Dysfunction in Women with Breast Cancer
**This study is closed to recruitment**
Up to 50% of women with breast cancer experience sleep disturbance because of their cancer diagnosis and treatment. This study will help us to understand how sleep before, during, and after breast cancer treatment might influence the development of other side effects such as difficulty remembering things and paying attention. This information may be used to help develop targeted prevention and/or intervention programs to help other women in the future.
Study Findings
Click below to learn more about the results of this study:
1. Factors Associated with Cognitive Impairment During the First
Year of Treatment for Nonmetastatic Breast Cancer
Published Abstracts
SLEEP 2019 - 0826 A Comparison of Pre-Treatment Sleep and Symptom Profiles in Age-Matched Breast and Prostate Cancer Patients
SLEEP 2019 - 0827 Prevalence And Factors Associated With Pre-treatment Insomnia Symptoms In Women With Early Stage Breast Cancer
SLEEP 2019 - 0828 Pre-Treatment Insomnia Symptoms and Perceived Cognitive Impairment in Newly Diagnosed Women with Early Stage Breast Cancer
SLEEP 2020 - 1036 Does Diary and Actigraphy Measured Sleep Differ Between Good and Poor Sleepers During Breast Cancer Treatment?
SLEEP 2020 - 1037 One Year Trajectory of Insomnia and Comorbid Symptoms in Women With Early Stage Breast Cancer
SLEEP 2020 - 1045 Impact Of Pre-treatment Sleep And Menopausal Status On Sleep Quality In The 12 Months Following A Breast Cancer Diagnosis
CAPO 2020 - 43 | A Comparison of Sleep and Symptom Profiles in Age-Matched Breast and Prostate Cancer Patients One-Year Post-Diagnosis
CAPO 2020 - 76 | Self-Rated Fatigue, Perceived Cognitive Function, Depression, and Anxiety in Women with Breast Cancer in the First Year of Treatment
IPOS 2022 - 129 | Impact of Rural or Urban Status on Sociodemographic Characteristics and Cancer Treatments
IPOS 2022 - 130 | Impact of Poor Sleep on Fatigue among Women with Non-Metastatic Breast Cancer
IPOS 2022 - 147 | Executive Function Alterations During the First Year of Breast Cancer Treatment
Investigators
Primary Investigator:
Sheila N. Garland, PhD
(Department of Psychology, Faculty of Science and Division of Oncology, Faculty of Medicine)
Co-Investigators:
Kara Laing, MD, FRCPC (Division of Oncology, Faculty of Medicine),
Joy McCarthy, MD, FRCPC (Division of Oncology, Faculty of Medicine),
Melanie Seal MD, FRCPC (Division of Oncology, Faculty of Medicine),
Gerard Farrell, MD (Division of Family Medicine, Faculty of Medicine)
Supported by a grant from Memorial University
